Novo-Nordisk

NVO-N

NYSE:NVO

69.44
0.13 (0.19%)
Novo Nordisk is a Danish multinational pharmaceutical company headquartered in Bagsværd, Denmark, with production facilities in eight countries, and affiliates or offices in 75 countries.
More at Wikipedia
NVO Fundamental Data  by TradingView
NVO Chart  by TradingView
Technical Analysis for NVO  by TradingView

Analysis and Opinions about NVO-N

Signal
Opinion
Expert
BUY
BUY
Novo-Nordisk (NVO-N)
September 14, 2020
The largest maker of insulin in the world. They have a strong diabetes franchise. Type diabetes is growing incredibly quickly around the world. They are one of the few companies that are involved in Diabetes. He thinks it will continue to accelerate and why this one will do well. It is a great story at 21 times earnings and 2% dividend yield. He will continue to buy it.
Show full opinionHide full opinion
Novo-Nordisk (NVO-N)
September 14, 2020
The largest maker of insulin in the world. They have a strong diabetes franchise. Type diabetes is growing incredibly quickly around the world. They are one of the few companies that are involved in Diabetes. He thinks it will continue to accelerate and why this one will do well. It is a great story at 21 times earnings and 2% dividend yield. He will continue to buy it.
biotechnology/pharmaceutical
0 Comments
Paul Harris, CFA

☆ Unlock Ratings

Price
$66.725
Owned
Yes
BUY
BUY
Novo-Nordisk (NVO-N)
August 25, 2020
If The Democrats Their goal is to sell outside the U.S. which they have done successfully, which have increased revenues, profits and dividends. Most importantly, their pill will replace people with type 2 diabetes from injecting insulin and helps people lose weight. They are the biggest insulin-maker in the world. This will be a big mover in coming years in pharma. You can take profits if the stock has moved up and is outsized in your portfolio.
Show full opinionHide full opinion
Novo-Nordisk (NVO-N)
August 25, 2020
If The Democrats Their goal is to sell outside the U.S. which they have done successfully, which have increased revenues, profits and dividends. Most importantly, their pill will replace people with type 2 diabetes from injecting insulin and helps people lose weight. They are the biggest insulin-maker in the world. This will be a big mover in coming years in pharma. You can take profits if the stock has moved up and is outsized in your portfolio.
biotechnology/pharmaceutical
0 Comments
David Driscoll

☆ Unlock Ratings

Price
$66.295
Owned
Yes
PAST TOP PICK
PAST TOP PICK
Novo-Nordisk (NVO-N)
August 20, 2020
(A Top Pick Sep 26/19, Up 29%) Diabetes and hemophilia. Diabetes continues to grow. NVO is at the sweet spot of that. Obesity will become a bigger and bigger issue.
Show full opinionHide full opinion
Novo-Nordisk (NVO-N)
August 20, 2020
(A Top Pick Sep 26/19, Up 29%) Diabetes and hemophilia. Diabetes continues to grow. NVO is at the sweet spot of that. Obesity will become a bigger and bigger issue.
biotechnology/pharmaceutical
0 Comments
Paul Harris, CFA

☆ Unlock Ratings

Price
$66.440
Owned
Yes
PAST TOP PICK
PAST TOP PICK
Novo-Nordisk (NVO-N)
July 21, 2020
(A Top Pick Aug 15/19, Up 38%) The biggest producer of insulin in the world. Type 2 diabetes is rapidly growing which helps NVO's growth. Very well-run. They have an obesity drug. A great demographic story. He continues to like it. He'd buy it here.
Show full opinionHide full opinion
Novo-Nordisk (NVO-N)
July 21, 2020
(A Top Pick Aug 15/19, Up 38%) The biggest producer of insulin in the world. Type 2 diabetes is rapidly growing which helps NVO's growth. Very well-run. They have an obesity drug. A great demographic story. He continues to like it. He'd buy it here.
biotechnology/pharmaceutical
0 Comments
Paul Harris, CFA

☆ Unlock Ratings

Price
$68.765
Owned
Yes
BUY WEAKNESS
BUY WEAKNESS
Novo-Nordisk (NVO-N)
February 7, 2020
International sales were up 11% and US at 1% due to pricing issues there. They are picking up market shares which gives them pricing power and allows them to go into India and China to earn higher margins. Getting out of the US is important for them. Once you get a moat around their product, the oral insulin pill and weight loss, it's smooth sailing. He's owned this since 1995. There are periods they struggle but over time, it's a gift that keeps giving. With the number of diabetics growing around the world, they will have good demand for its products. Right now, he would pause but he would have it in your portfolio.
Show full opinionHide full opinion
Novo-Nordisk (NVO-N)
February 7, 2020
International sales were up 11% and US at 1% due to pricing issues there. They are picking up market shares which gives them pricing power and allows them to go into India and China to earn higher margins. Getting out of the US is important for them. Once you get a moat around their product, the oral insulin pill and weight loss, it's smooth sailing. He's owned this since 1995. There are periods they struggle but over time, it's a gift that keeps giving. With the number of diabetics growing around the world, they will have good demand for its products. Right now, he would pause but he would have it in your portfolio.
biotechnology/pharmaceutical
0 Comments
David Driscoll

☆ Unlock Ratings

Price
$63.250
Owned
Yes
COMMENT
COMMENT
Novo-Nordisk (NVO-N)
January 17, 2020
They have good exposure to the diabetes market, though less specialized growth in the next 10 years. They don't own it because their options are not liquid enough.
Show full opinionHide full opinion
Novo-Nordisk (NVO-N)
January 17, 2020
They have good exposure to the diabetes market, though less specialized growth in the next 10 years. They don't own it because their options are not liquid enough.
biotechnology/pharmaceutical
0 Comments
Paul MacDonald

☆ Unlock Ratings

Price
$61.310
Owned
No
BUY
BUY
Novo-Nordisk (NVO-N)
January 13, 2020
All pharma companies face pricing pressure in a US election year, because US candidates take shots at drug pricing. Also pharma companies need to keep putting new, successful drugs. NN succeeds in putting out new diabetes drugs (they lead this product segment globally).
Show full opinionHide full opinion
Novo-Nordisk (NVO-N)
January 13, 2020
All pharma companies face pricing pressure in a US election year, because US candidates take shots at drug pricing. Also pharma companies need to keep putting new, successful drugs. NN succeeds in putting out new diabetes drugs (they lead this product segment globally).
biotechnology/pharmaceutical
0 Comments
Brett Girard, CPA, CA, CFA

☆ Unlock Ratings

Price
$58.970
Owned
Yes
DON'T BUY
DON'T BUY
Novo-Nordisk (NVO-N)
December 2, 2019
He has avoided it because insulin and products to replace it have had a lot of price increases and he fears they will be looked at by politicians. It is a very defensive issue and should do better when the economy slows.
Show full opinionHide full opinion
Novo-Nordisk (NVO-N)
December 2, 2019
He has avoided it because insulin and products to replace it have had a lot of price increases and he fears they will be looked at by politicians. It is a very defensive issue and should do better when the economy slows.
biotechnology/pharmaceutical
0 Comments
David Fingold

☆ Unlock Ratings

Price
$56.020
Owned
No
TOP PICK
TOP PICK
Novo-Nordisk (NVO-N)
November 29, 2019
FDA approval for a tablet diabetes drug. China and India will have a growing market for this as well. The trend will help the bottom line and profitability. He's owned it since 1997, and though it hasn't done much in the last 5 years, it is picking up. They are also completely off the grid and is very environmental. (Analysts’ price target is $62.73)
Show full opinionHide full opinion
Novo-Nordisk (NVO-N)
November 29, 2019
FDA approval for a tablet diabetes drug. China and India will have a growing market for this as well. The trend will help the bottom line and profitability. He's owned it since 1997, and though it hasn't done much in the last 5 years, it is picking up. They are also completely off the grid and is very environmental. (Analysts’ price target is $62.73)
biotechnology/pharmaceutical
0 Comments
David Driscoll

☆ Unlock Ratings

Price
$56.150
Owned
Yes
BUY WEAKNESS
BUY WEAKNESS
Novo-Nordisk (NVO-N)
November 5, 2019

The pharma sector. Any picks? Pharma's problem is the US election cycle when candidates always bash big pharma. But these stocks are not expensive now, like JNJ which boasts 3 divisions (consumer, medical devices and pharma); and Novo Nordisk, which offers a diabetes pill and obesity pill. Buy a small position now as well as when they pull back during the election campaign, and certainly after the election. NVO increases its dividend perennially. The Dems and Republicans are equally critical of pharma.

Show full opinionHide full opinion
Novo-Nordisk (NVO-N)
November 5, 2019

The pharma sector. Any picks? Pharma's problem is the US election cycle when candidates always bash big pharma. But these stocks are not expensive now, like JNJ which boasts 3 divisions (consumer, medical devices and pharma); and Novo Nordisk, which offers a diabetes pill and obesity pill. Buy a small position now as well as when they pull back during the election campaign, and certainly after the election. NVO increases its dividend perennially. The Dems and Republicans are equally critical of pharma.

biotechnology/pharmaceutical
0 Comments
Paul Harris, CFA

☆ Unlock Ratings

Price
$56.460
Owned
Yes
TOP PICK
TOP PICK
Novo-Nordisk (NVO-N)
September 26, 2019
Their business is in hemophilia and diabetes (450 million have it globally and the number will rise). They make an obesity drug (a pill, that's showing growth) and sell the most insulin in the world. (Analysts’ price target is $56.45)
Show full opinionHide full opinion
Novo-Nordisk (NVO-N)
September 26, 2019
Their business is in hemophilia and diabetes (450 million have it globally and the number will rise). They make an obesity drug (a pill, that's showing growth) and sell the most insulin in the world. (Analysts’ price target is $56.45)
biotechnology/pharmaceutical
0 Comments
Paul Harris, CFA

☆ Unlock Ratings

Price
$52.190
Owned
Yes
TOP PICK
TOP PICK
Novo-Nordisk (NVO-N)
August 15, 2019
Big franchise is in diabetes. Explosive, secular growth in diabetes, and NVO is the largest producer of insulin in the world. Plus biopharma business. Yield is 1.77%. (Analysts’ price target is $54.45)
Show full opinionHide full opinion
Novo-Nordisk (NVO-N)
August 15, 2019
Big franchise is in diabetes. Explosive, secular growth in diabetes, and NVO is the largest producer of insulin in the world. Plus biopharma business. Yield is 1.77%. (Analysts’ price target is $54.45)
biotechnology/pharmaceutical
0 Comments
Paul Harris, CFA

☆ Unlock Ratings

Price
$50.740
Owned
Yes
BUY
BUY
Novo-Nordisk (NVO-N)
August 2, 2019
Over the next 25 years, type 2 diabetes will grow 55% led by India and China. Demand will be there. Novo needs to go and get this market. Starting to show better revenues and operating margins. They also have a new drug that is not just for diabetes but for weight loss.
Show full opinionHide full opinion
Novo-Nordisk (NVO-N)
August 2, 2019
Over the next 25 years, type 2 diabetes will grow 55% led by India and China. Demand will be there. Novo needs to go and get this market. Starting to show better revenues and operating margins. They also have a new drug that is not just for diabetes but for weight loss.
biotechnology/pharmaceutical
0 Comments
David Driscoll

☆ Unlock Ratings

Price
$48.590
Owned
Unknown
HOLD
HOLD
Novo-Nordisk (NVO-N)
June 21, 2019
About to come out with a pill instead of injections. Stock has popped recently. Type 2 diabetics are going to increase 50% in the next 2 years, mainly in India and China. Margins are being squeezed. Have to work harder to get sales. Likes what they're doing. Leaders in the industry.
Show full opinionHide full opinion
Novo-Nordisk (NVO-N)
June 21, 2019
About to come out with a pill instead of injections. Stock has popped recently. Type 2 diabetics are going to increase 50% in the next 2 years, mainly in India and China. Margins are being squeezed. Have to work harder to get sales. Likes what they're doing. Leaders in the industry.
biotechnology/pharmaceutical
0 Comments
David Driscoll

☆ Unlock Ratings

Price
$50.840
Owned
Unknown
TOP PICK
TOP PICK
Novo-Nordisk (NVO-N)
April 24, 2019
The play is the growth in diabetes -- 11% per year. More drugs and medications will be required and this company has the best market share in the space. As this is a global issue, they worldwide coverage is a great advantage. Yield 3.2% (Analysts’ price target is $53.45)
Show full opinionHide full opinion
Novo-Nordisk (NVO-N)
April 24, 2019
The play is the growth in diabetes -- 11% per year. More drugs and medications will be required and this company has the best market share in the space. As this is a global issue, they worldwide coverage is a great advantage. Yield 3.2% (Analysts’ price target is $53.45)
biotechnology/pharmaceutical
0 Comments
Kash Pashootan

☆ Unlock Ratings

Price
$48.370
Owned
Yes
Showing 1 to 15 of 87 entries
Next Page

Novo-Nordisk(NVO-N) Rating

Ranking : 4 out of 5

Bullish - Buy Signals / Votes : 7

Neutral - Hold Signals / Votes : 0

Bearish - Sell Signals / Votes : 1

Total Signals / Votes : 8

Stockchase rating for Novo-Nordisk is calculated according to the stock experts' signals. A high score means experts mostly recommend to buy the stock while a low score means experts mostly recommend to sell the stock.

Novo-Nordisk(NVO-N) Frequently Asked Questions

What is Novo-Nordisk stock symbol?

Novo-Nordisk is a American stock, trading under the symbol NVO-N on the New York Stock Exchange (NVO). It is usually referred to as NYSE:NVO or NVO-N

Is Novo-Nordisk a buy or a sell?

In the last year, 8 stock analysts published opinions about NVO-N. 7 analysts recommended to BUY the stock. 1 analyst recommended to SELL the stock. The latest stock analyst recommendation is BUY. Read the latest stock experts' ratings for Novo-Nordisk.

Is Novo-Nordisk a good investment or a top pick?

Novo-Nordisk was recommended as a Top Pick by Paul Harris, CFA on 2020-09-14. Read the latest stock experts ratings for Novo-Nordisk.

Why is Novo-Nordisk stock dropping?

Earnings reports or recent company news can cause the stock price to drop. Read stock experts’ recommendations for help on deciding if you should buy, sell or hold the stock.

Is Novo-Nordisk worth watching?

8 stock analysts on Stockchase covered Novo-Nordisk In the last year. It is a trending stock that is worth watching.

What is Novo-Nordisk stock price?

On 2020-09-18, Novo-Nordisk (NVO-N) stock closed at a price of $69.44.

PixFuture exclusive partner.
© Stockchase Inc.